ProSight

Company Overview

Snapshot

Founded in May 2017 by Avi Simon and Meir Weksler, ProSight operates with 1–10 employees. The company has raised $6.05M across two funding rounds. ProSight is developing a real-time ex-vivo biopsy samples scanner, aiming to transform prostate cancer diagnosis.

Business overview

ProSight is a medical device startup specializing in Health Tech & Life Sciences, specifically Diagnostics Devices within the Medical Devices sector. Spun out of the Weizmann Institute of Science, the company develops an XRF-guided biopsy system for real-time ex-vivo scanning of fresh biopsy samples. This technology leverages novel biomarkers, such as zinc depletion, to improve prostate cancer diagnosis by providing real-time cancer grading and guidance during biopsy procedures. ProSight serves the healthcare industry, particularly healthcare providers, with a focus on addressing limitations in current prostate cancer biopsy methods.

Company Intelligence Q&A

What is ProSight's core technology?

ProSight's core technology is an XRF-guided biopsy system designed for real-time ex-vivo scanning of fresh biopsy samples. This system aims to improve prostate cancer diagnosis by identifying cancer severity based on biomarkers like zinc depletion.

When was ProSight founded and by whom?

ProSight was founded in May 2017 by Avi Simon and Meir Weksler.

How much capital has ProSight raised to date?

ProSight has raised a total of $6.05M across two funding rounds.

What is ProSight's primary focus in the healthcare sector?

ProSight's primary focus is on transforming prostate cancer diagnosis by addressing the limitations of current biopsy procedures through its real-time ex-vivo biopsy samples scanner.